Intermittent Androgen Deprivation for Biochemically Recurrent Prostate Cancer: First Do No Harm

Anthony V Serritella; Sarah E Fenton; Maha Hussain

doi:10.1016/j.euf.2023.01.009

Intermittent Androgen Deprivation for Biochemically Recurrent Prostate Cancer: First Do No Harm

Eur Urol Focus. 2023 May;9(3):407-408. doi: 10.1016/j.euf.2023.01.009. Epub 2023 Jan 25.

Authors

Anthony V Serritella¹, Sarah E Fenton¹, Maha Hussain²

Affiliations

¹ Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
² Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address: maha.hussain@northwestern.edu.

PMID: 36707276
DOI: 10.1016/j.euf.2023.01.009

Abstract

Intermittent androgen deprivation therapy in patients with prostate cancer and biochemical relapse does not prolong survival or improve quality of life.

Publication types

Comment

MeSH terms

Androgen Antagonists / adverse effects
Androgens
Chronic Disease
Humans
Male
Neoplasm Recurrence, Local / drug therapy
Prostatic Neoplasms*
Quality of Life

Substances

Androgen Antagonists
Androgens